Comparative effects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus

Brain Research

Volumn 892, Issue 1, 2001, Pages 51-62

  Armstrong, Carolyn ^a   Leong, Wing ^a   Lees, Gordon J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Ammonium tetrathiomolybdate; Copper; Hippocampus; Iron; Metal chelating agent; Neurotoxicity; Zinc

Indexed keywords

CHELATING AGENT; COPPER SULFATE; DEFEROXAMINE MESYLATE; DISODIUM BATHOCUPROINE DISULPHONATE; EDETIC ACID; FERRIC SULFATE; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; SODIUM CHLORIDE; TETRATHIOMOLYBDATE AMMONIUM; UNCLASSIFIED DRUG; ZINC CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG POTENCY; DRUG SPECIFICITY; HIPPOCAMPUS; LIMBIC CORTEX; MALE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SEIZURE;

ANIMALS; CELL SURVIVAL; CHELATING AGENTS; COPPER SULFATE; CYTOTOXINS; DEFEROXAMINE; EDETIC ACID; ETHYLENEDIAMINES; FERRIC COMPOUNDS; HIPPOCAMPUS; MALE; NEURONS; PHENANTHROLINES; RATS; RATS, WISTAR; ZINC;

EID: 0035895830     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)03195-4     Document Type: Article

References (109)

1. Increased brain uptake of copper and zinc in mice caused by diethyldithiocarbamate
2. Depletion of intracellular zinc produces protein synthesis-dependent neuronal apoptosis in mouse cortical culture
3. Diethyldithiocarbamate and brain copper
4. Diethyldithiocarbamate, copper and neurological disorders
5. 2+ homeostasis in Ehrlich and Yoshida carcinomas
6. 2+-exchanger
7. Limbic seizure and brain damage produced by kainic acid: Mechanisms and relevance to human temporal lobe epilepsy
8. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons
9. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: Implication for Parkinson's disease
10. Intranigral iron injection induces behavioral and biochemical 'Parkinsonism' in rats
11. Deferoxamine (Desferrioxamine). New toxicities for an old drug
12. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients
13. Treatment of Wilson's disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy
14. Worsening of neurological syndrome in patients with Wilson's disease with initial penicillamine therapy
15. 2+ inhibits α-ketoglutarate-stimulated mitochondrial respiration and the isolated α-ketoglutarate dehydrogenase complex
16. Zinc neurotoxicity in cortical cell culture
17. Seizures and neuronal damage in mice lacking vesicular zinc
18. A histochemical study of iron, transferrin and ferritin in Alzheimer diseased brains
19. Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc
20. Prevention of zinc neurotoxicity in vivo by N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN)
21. Nitric oxide generators produce accumulation of chelatable zinc in hippocampal neuronal perikarya
22. Diverse effects of metal chelating agents on the neuronal cytotoxicity of zinc in the hippocampus
23. Prevention of zinc neurotoxicity in vivo by N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN)
24. The effects of disulfiram on the hippocampus and cerebellum of the rat brain: A study on oxidative stress
25. Wilson's disease and epilepsy
26. +-ATPase
27. Desmethyl tirilazad improves neurologic function after hypoxic ischemic brain injury in piglets
28. Translocation of zinc may contribute to seizure-induced death of neurons
29. Aberrant copper chemistry as a major mediator of oxidative stress in a human cellular model of amyotrophic lateral sclerosis
30. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders
31. Hydroxyl radicals, iron, oxidative stress, and neurodegeneration
32. Oxygen radicals as key mediators in neurological disease: Fact or fiction?
33. Metal (molybdenum, copper) accumulation and retention in brain, pituitary and other organs of ammonium tetrathiomolybdate-treated sheep
34. Endogenous mechanisms of neuroprotection: Role of zinc, copper and carnosine
35. Risks of parenteral deferoxamine for acute iron poisoning
36. The Ab peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction
37. The selective inhibition of hippocampal glutamic acid decarboxylase in zinc-induced epileptic seizures
38. 2+
39. The effect of ligands on the uptake of iron by cells in culture
40. 2+ entry produces oxidative neuronal necrosis in cortical cell cultures
41. Zinc-induced cortical neuronal death with features of apoptosis and necrosis: Mediation by free radicals
42. Hydrogen peroxide-mediated degradation of protein: Different oxidation modes of copper- and iron-dependent hydroxyl radicals on the degradation of albumin
43. Metabolism of administered triethylene tetramine dihydrochloride in humans
44. The role of zinc in selective neuronal death after transient global cerebral ischemia
45. Neurotoxic effects of copper, inhibition of glycolysis and glycolytic enzymes
46. Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease
47. Iron bound to the lipophilic iron chelator, 8-hydroxyquinoline, causes DNA strand breakage in cultured lung cells
48. Accumulation of zinc in degenerating hippocampal neurons of ZnT3-null mice after seizures: Evidence against synaptic vesicle origin
49. Effects of anaesthetics, anticonvulsants and glutamate antagonists on kainic acid-induced local and distal neuronal loss
50. The neurotoxicity of zinc in the rat hippocampus
51. Brain lesions induced by specific and non-specific inhibitors of sodium-potassium ATPase
52. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions
53. Altered systemic iron metabolism in Parkinson's disease
54. Copper, iron and zinc in Alzheimer's disease senile plaques
55. Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia
56. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: An electrophysiological study of cerebral and visual function
57. Chelation of intracellular zinc triggers apoptosis in mature thymocytes
58. Intramuscular desferrioxamine in patients with Alzheimer's disease
59. Reversibility of Scrapie inactivation is enhanced by copper
60. Proconvulsant action of diethyldithiocarbamate in stimulation of the perforant path
61. Diethyldithiocarbamate and dithizone augment the toxicity of kainic acid
62. Amyotrophic lateral sclerosis associated with mutations in superoxide dismutase: A putative mechanism of degeneration
63. Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide
64. The amyloid precursor protein of Alzheimer's disease in the reduction of Copper (II) to Copper (I)
65. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice
66. Apoptosis induced by chelation of intracellular zinc is associated with depletion of cellular reduced glutathione level in rat hepatocytes
67. Comparative mechanism and toxicity of tetra-and dithiomolybdates in the removal of copper
68. Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats
69. Involvement of zinc in intracellular oxidant/antioxidant balance
70. Features of seizures and behavioral changes induced by intrahippocampal injection of zinc sulfate in the rabbit: A new experimental model of epilepsy
71. Hippocampal epileptogenesis produced by electrolytic iron deposition in the rat dentate gyrus
72. Experimental pharmacologic cerebroprotection
73. The toxic effects of desferrioxamine
74. Prions are copper-binding proteins
75. Generation of reactive oxygen species by the redox cycling of nitroprusside
76. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease
77. 3+-quin2 chelate and the subsequent formation of oxidizing species
78. The neuroprotective effect of deferoxamine in the hypoxic-ischemic immature mouse brain
79. Alzheimer's precursor protein and the use of bathocuproine for determining reduction of copper (II)
80. Iron induces degeneration of nigrostriatal neurons
81. Measurement of intracellular free zinc in living cortical neurons: Routes of entry
82. 2+-permeable AMPA/kainate channels triggers prolonged mitochondrial superoxide production
83. Zinc release from Xenopus transcription factor IIIA induced by chemical modifications
84. + and inhibition of glycolysis
85. Selective lesions by manganese and extensive damage by iron after injection into rat striatum and hippocampus
86. Use of allopurinol and desferoxamine in cellular protection during ischemia
87. The effect of subcutaneous tetrathiomolybdate administration on copper and iron metabolism, including their regional distribution in the brain, in the Long-Evans Cinnamon rat, a bona fide animal model for Wilson's disease
88. Evidence that synaptically-released zinc contributes to neuronal injury after traumatic brain injury
89. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains
90. Possible role of zinc in the selective degeneration of dentate hilar neurons after cerebral ischemia in the adult rat
91. Iron-chelating agents in non-iron overload conditions
92. Strain-specific prion-protein conformation determined by metal ions
93. Management of penicillamine neuropathy in Wilson's disease: A new chelating agent
94. Pathophysiological mechanisms of brain damage from status epilepticus
95. AMPA receptor activation potentiates zinc neurotoxicity
96. The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures
97. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis
98. Epileptiform activity initiated by pial iontophoresis of ferrous and ferric chloride on rat cerebral cortex
99. Chronic epileptiform discharges induced by injection of iron into rat and cat cortex
100. Inhibition of DNA-binding activity of NF-κB by gold compounds in vitro
101. Aluminum chelation: Chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine
102. Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Sp1
103. Zinc transfer from transcription factor IIIA fingers to thionein clusters
104. Basic FGF, NGF, and IGFs protect hippocampal and cortical neurons against iron-induced degeneration